Newsletter
The Next Generation of Psychedelics Focused on Patient Access with Blake Mandell, Co-founder and President of Transcend Therapeutics

Outcomes Rocket

The Next Generation of Psychedelics Focused on Patient Access with Blake Mandell, Co-founder and President of Transcend Therapeutics

October 14, 2021

The Next Generation of Psychedelics Focused on Patient Access with Blake Mandell, Co-founder and President of Transcend Therapeutics

In this episode of the Outcomes Rocket Pharma, we are privileged to host the outstanding Blake Mandell, co-founder and President of Transcend Therapeutics. Transcend Therapeutics discovers, develops, and delivers next-generation medicines to work towards a world in which people no longer suffer from neuropsychiatric disorders.

In our conversation, we cover Transcend’s goal to discover and develop drugs from analogs of classic psychedelics and how they fit better into the care paradigm. Blake discusses the current statistics of adults suffering from major depressive disorders in the U.S, his vision of where Transcend will be in the next years, challenges, the Multidisciplinary Approach for Psychedelic Studies (MAPS), and more. He also shares his insights on working with psychedelic substances and the possible treatments it offers for patients suffering from depression and other neuropsychiatric disorders.

Click this link to the show notes, transcript, and resources: outcomesrocket.health

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

Subscribe to Health Podcast Network

Join Our Newsletter

Proudly supported by:

cover
How is Parkinson’s Disease Diagnosed? And How Is a Care Team Created? Parkinson’s disease can’t be diagnosed through a simple blood test or scan. After a referral from a primary care doctor, it often takes visits to a neurologist or movement disorder specialist before receiving a clinical diagnosis.